Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200390647> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4200390647 endingPage "S702" @default.
- W4200390647 startingPage "S702" @default.
- W4200390647 abstract "Abstract Background Elevated resistance rates have been reported in ICUs. Aztreonam (ATM) combined with avibactam (AVI) is being developed for use against drug-resistant Enterobacterales (Ebact), including metallo-β-lactamase (MBL)-positive isolates. We examined the activity of ATM-AVI and comparators against Ebact isolates collected from geriatric patients in ICU and non-ICU wards as part of the ATLAS surveillance program. Methods 23754 non-duplicate Ebact isolates were collected in 53 countries in Asia/Pacific (excluding mainland China and India), Europe, Latin America, and Middle East/Africa from patients ≥65 years with lower respiratory tract (LRTI), urinary tract (UTI), skin and soft tissue (SSTI), intra-abdominal (IAI), and bloodstream (BSI) infections. Susceptibility testing was performed by CLSI broth microdilution and values interpreted using CLSI 2021 breakpoints. PCR and sequencing were used to determine the β-lactamase genes present in isolates with meropenem MIC >1 µg/mL, and Escherichia coli, Klebsiella spp. and Proteus mirabilis with ATM or ceftazidime MIC >1 µg/mL. Results Susceptibility of the studied comparator agents was generally slightly lower among Ebact from BSI than other infection types (Table). Susceptibility was also generally lower among Ebact from ICU than non-ICU wards by up to 10 percentage points, and MIC90 values were up to 32-fold higher. ATM-AVI MIC90 values were within one doubling-dilution across all studied strata (0.12-0.25 µg/mL), were comparable to or lower than for meropenem in all strata, and were 2 to ≥9 dilutions lower than all other tested comparators. MBL-positive Ebact were found in 1.5% of LRTI (n=91), 1.2% of UTI (n=70), 1.1% of SSTI (n=52), 1.3% of BSI (n=49), and 0.7% of IAI isolates (n=22). MBL-positive rates were higher among ICU (1.7%, n=101) than non-ICU isolates (1.0%, n=183). ATM-AVI MIC90 values were 0.5 µg/mL against MBL-positive isolates from all ward and infection types except SSTI (MIC90 0.25 µg/mL) and BSI (MIC90 1 µg/mL), 2-4 dilutions lower than tigecycline and at least 5-10 dilutions lower than the other comparators. Results Table Conclusion ATM-AVI could provide a valuable therapeutic option for treatment of infections caused by Ebact in patients ≥65 years old in both ICU and non-ICU wards. Disclosures Sibylle Lob, PhD, IHMA (Employee)Pfizer, Inc. (Independent Contractor) Krystyna Kazmierczak, PhD, IHMA (Employee)Pfizer, Inc. (Independent Contractor) Francis Arhin, PhD, Pfizer, Inc. (Employee) Daniel F. Sahm, PhD, IHMA (Employee)Pfizer, Inc. (Independent Contractor)" @default.
- W4200390647 created "2021-12-31" @default.
- W4200390647 creator A5017159626 @default.
- W4200390647 creator A5030449858 @default.
- W4200390647 creator A5038009031 @default.
- W4200390647 creator A5066677972 @default.
- W4200390647 date "2021-11-01" @default.
- W4200390647 modified "2023-09-23" @default.
- W4200390647 title "1225. In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Enterobacterales Collected from Geriatric Patients in ICU and non-ICU wards, ATLAS Surveillance Program 2016-2019" @default.
- W4200390647 doi "https://doi.org/10.1093/ofid/ofab466.1417" @default.
- W4200390647 hasPublicationYear "2021" @default.
- W4200390647 type Work @default.
- W4200390647 citedByCount "0" @default.
- W4200390647 crossrefType "journal-article" @default.
- W4200390647 hasAuthorship W4200390647A5017159626 @default.
- W4200390647 hasAuthorship W4200390647A5030449858 @default.
- W4200390647 hasAuthorship W4200390647A5038009031 @default.
- W4200390647 hasAuthorship W4200390647A5066677972 @default.
- W4200390647 hasBestOaLocation W42003906471 @default.
- W4200390647 hasConcept C126322002 @default.
- W4200390647 hasConcept C176947019 @default.
- W4200390647 hasConcept C2775933652 @default.
- W4200390647 hasConcept C2776968632 @default.
- W4200390647 hasConcept C2777050379 @default.
- W4200390647 hasConcept C2777637488 @default.
- W4200390647 hasConcept C2779375183 @default.
- W4200390647 hasConcept C2779631663 @default.
- W4200390647 hasConcept C2780416669 @default.
- W4200390647 hasConcept C2780950330 @default.
- W4200390647 hasConcept C501593827 @default.
- W4200390647 hasConcept C523546767 @default.
- W4200390647 hasConcept C54355233 @default.
- W4200390647 hasConcept C71924100 @default.
- W4200390647 hasConcept C86803240 @default.
- W4200390647 hasConcept C89423630 @default.
- W4200390647 hasConcept C94665300 @default.
- W4200390647 hasConceptScore W4200390647C126322002 @default.
- W4200390647 hasConceptScore W4200390647C176947019 @default.
- W4200390647 hasConceptScore W4200390647C2775933652 @default.
- W4200390647 hasConceptScore W4200390647C2776968632 @default.
- W4200390647 hasConceptScore W4200390647C2777050379 @default.
- W4200390647 hasConceptScore W4200390647C2777637488 @default.
- W4200390647 hasConceptScore W4200390647C2779375183 @default.
- W4200390647 hasConceptScore W4200390647C2779631663 @default.
- W4200390647 hasConceptScore W4200390647C2780416669 @default.
- W4200390647 hasConceptScore W4200390647C2780950330 @default.
- W4200390647 hasConceptScore W4200390647C501593827 @default.
- W4200390647 hasConceptScore W4200390647C523546767 @default.
- W4200390647 hasConceptScore W4200390647C54355233 @default.
- W4200390647 hasConceptScore W4200390647C71924100 @default.
- W4200390647 hasConceptScore W4200390647C86803240 @default.
- W4200390647 hasConceptScore W4200390647C89423630 @default.
- W4200390647 hasConceptScore W4200390647C94665300 @default.
- W4200390647 hasIssue "Supplement_1" @default.
- W4200390647 hasLocation W42003906471 @default.
- W4200390647 hasLocation W42003906472 @default.
- W4200390647 hasOpenAccess W4200390647 @default.
- W4200390647 hasPrimaryLocation W42003906471 @default.
- W4200390647 hasRelatedWork W2580291684 @default.
- W4200390647 hasRelatedWork W2898816813 @default.
- W4200390647 hasRelatedWork W2901057130 @default.
- W4200390647 hasRelatedWork W3120863683 @default.
- W4200390647 hasRelatedWork W3196668908 @default.
- W4200390647 hasRelatedWork W4200348663 @default.
- W4200390647 hasRelatedWork W4223455524 @default.
- W4200390647 hasRelatedWork W4232272478 @default.
- W4200390647 hasRelatedWork W4306644058 @default.
- W4200390647 hasRelatedWork W4311739924 @default.
- W4200390647 hasVolume "8" @default.
- W4200390647 isParatext "false" @default.
- W4200390647 isRetracted "false" @default.
- W4200390647 workType "article" @default.